| Title |
Dextromethorphan/Quinidine: A Review of Its Use in Adults with Pseudobulbar Affect
|
|---|---|
| Published in |
Drugs, November 2014
|
| DOI | 10.1007/s40265-014-0328-z |
| Pubmed ID | |
| Authors |
Lily P. H. Yang, Emma D. Deeks |
| Abstract |
Fixed-dose dextromethorphan/quinidine capsules (Nuedexta(®)) utilize quinidine to inhibit the metabolism of dextromethorphan, enabling high plasma dextromethorphan concentrations to be reached without using a larger dose of the drug. The drug combination is the first treatment to be approved for pseudobulbar affect (PBA), a condition of contextually inappropriate/exaggerated emotional expression that often occurs in adults with neurological damage conditions, such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, traumatic brain injury, Alzheimer's disease or Parkinson's disease. Dextromethorphan/quinidine at the recommended dosages of 20/10 or 30/10 mg twice daily reduced the rate of PBA episodes and improved PBA severity in a 12-week, double-blind, placebo-controlled trial in adults with ALS or MS (STAR), with further improvements in the severity of the condition observed in a 12-week open-label extension phase. Dextromethorphan/quinidine 20/10 mg twice daily also improved PBA secondary to dementia in a cohort of a 12-week noncomparative trial (PRISM II). The drug combination was generally well tolerated in these studies, with no particular safety or tolerability concerns. Although longer-term efficacy and tolerability data for dextromethorphan/quinidine 20/10 or 30/10 mg twice daily would be beneficial, current evidence indicates that it is a useful option in the treatment of adults with PBA. |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Korea, Republic of | 1 | 1% |
| Spain | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 68 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 14% |
| Other | 9 | 13% |
| Student > Bachelor | 8 | 11% |
| Researcher | 6 | 8% |
| Student > Doctoral Student | 6 | 8% |
| Other | 12 | 17% |
| Unknown | 20 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 23% |
| Psychology | 12 | 17% |
| Neuroscience | 7 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Nursing and Health Professions | 2 | 3% |
| Other | 6 | 8% |
| Unknown | 25 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 November 2022.
All research outputs
#2,975,749
of 23,025,074 outputs
Outputs from Drugs
#375
of 3,288 outputs
Outputs of similar age
#44,010
of 363,116 outputs
Outputs of similar age from Drugs
#6
of 26 outputs
Altmetric has tracked 23,025,074 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,288 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 363,116 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.